US 11,944,681 B2
HIV-1 neutralizing antibodies and uses thereof
Barton F. Haynes, Durham, NC (US); Hua-Xin Liao, Durham, NC (US); M. Anthony Moody, Durham, NC (US); LaTonya Williams, Durham, NC (US); Kevin J. Wiehe, Durham, NC (US); and Gilad Adi Ofek, College Park, MD (US)
Assigned to Duke University, Durham, NC (US); and University of Maryland, College Park, MD (US)
Filed by Duke University, Durham, NC (US); and University of Maryland, College Park, MD (US)
Filed on Jun. 24, 2021, as Appl. No. 17/357,725.
Application 17/357,725 is a continuation of application No. 15/559,314, granted, now 11,071,783, previously published as PCT/US2016/023488, filed on Mar. 21, 2016.
Claims priority of provisional application 62/261,233, filed on Nov. 30, 2015.
Claims priority of provisional application 62/260,100, filed on Nov. 25, 2015.
Claims priority of provisional application 62/222,057, filed on Sep. 22, 2015.
Claims priority of provisional application 62/191,095, filed on Jul. 10, 2015.
Claims priority of provisional application 62/191,054, filed on Jul. 10, 2015.
Claims priority of provisional application 62/135,309, filed on Mar. 19, 2015.
Prior Publication US 2022/0096632 A1, Mar. 31, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/42 (2006.01); A61K 31/18 (2006.01); A61K 39/44 (2006.01); A61P 31/18 (2006.01); C07K 16/10 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/42 (2013.01) [A61K 39/44 (2013.01); A61P 31/18 (2018.01); C07K 16/1045 (2013.01); A61K 2039/507 (2013.01); C07K 2299/00 (2013.01); C07K 2317/24 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 28 Claims
 
1. A recombinant antibody or fragment thereof comprising: a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR)1, a HCDR2, and a HCDR3 comprising amino acids at positions 26-33, 51-60 and 99-121 of SEQ ID NO: 230, SEQ ID NO: 240 or SEQ ID NO: 241, respectively and wherein the amino acid sequence of the heavy chain variable region outside of HCDR1, HCDR2, and HCDR3 has an overall sequence identity of at least 90% to SEQ ID NO: 230, SEQ ID NO: 240, or SEQ ID NO: 241; and a light chain variable region comprising a light chain complementarity determining region (LCDR)1, a LCDR2, and a LCDR3, comprising amino acids at positions 27-32, 50-52 and 89-99 of SEQ ID NO: 253, SEQ ID NO: 255 or SEQ ID NO: 261 respectively, and wherein the amino acid sequence of the light chain variable region outside of LCDR1, LCDR2, and LCDR3 has an overall sequence identity of at least 90% to SEQ ID NO: 253, SEQ ID NO: 255, or SEQ ID NO: 261, and wherein the antibody or fragment thereof binds gp41 MPER of HIV-1 envelope.